FDA announced that it had approved Zynteglo (betibeglogene autotemcel), a novel cell-based gene therapy for adult and pediatric patients with beta-thalassemia who need regular red blood cell transfusions.  Zynteglo, developed by Bluebird Bio (Nasdaq: BLUE), is administered as a single dose.  The product is indicated for adult and pediatric patients who need regular red blood…